双靶向CD19与CD22的双顺反子CAR-T细胞治疗复发/难治性大B细胞淋巴瘤患者
这项研究在复发/难治性大B细胞淋巴瘤患者中测试CD19/22双靶向CAR-T(AUTO3)联合帕博利珠单抗的安全性与疗效,52例接受AUTO3、48/52例接受帕博利珠单抗,中位随访21.6个月,总缓解率66%(完全缓解48.9%),完全缓解患者中54.4%预计≥12个月无进展。
要点
- AUTO3联合帕博利珠单抗在复发/难治性大B细胞淋巴瘤中安全性可控,1-2级细胞因子释放综合征见于18/52例(34.6%)。
- 总缓解率为66%,其中完全缓解48.9%、部分缓解17%;完全缓解患者的中位缓解持续时间未达到。
- 完全缓解患者中54.4%(95%CI:32.8-71.7)预计≥12个月无进展,所有缓解患者中为42.6%。
核心结论
- AUTO3联合或不联合帕博利珠单抗治疗复发/难治性大B细胞淋巴瘤安全,在54.4%的完全缓解患者中实现持久缓解,并与稳健的CAR-T扩增相关。
- 双靶向CAR-T或帕博利珠单抗均未能阻止相当比例患者复发,未来方向包括体内扩增更优的下一代AUTO3及筛选低抗原密度下有活性的CAR结合体。
研究设计与样本
- 研究纳入复发/难治性大B细胞淋巴瘤患者,测试CD19/22双靶向CAR-T(AUTO3)联合帕博利珠单抗(NCT03289455)。
- 52例患者接受AUTO3,48/52例接受帕博利珠单抗;中位年龄59岁(范围27-83),46/52例为III/IV期疾病,中位随访21.6个月。
- 终点包括毒性(主要)和缓解率(次要)。
主要发现
- 1-2级和3级细胞因子释放综合征分别影响18/52例(34.6%)和1/52例(1.9%),神经毒性见于4例患者(其中2/4例为3-4级),噬血细胞性淋巴组织细胞增多症影响2例患者。
- 在20例患者中测试了门诊给药,每例患者中位节省14个住院日。
- 总缓解率为66%(完全缓解48.9%,部分缓解17%);完全缓解患者的中位缓解持续时间未达到,所有缓解患者的中位缓解持续时间为8.3个月(95%CI:3.0-不可评估)。
- 完全缓解患者中54.4%(95%CI:32.8-71.7)和所有缓解患者中42.6%预计≥12个月无进展。
局限性
- 双靶向CAR-T或帕博利珠单抗均未能阻止相当比例患者复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. Multiantigen targeting and programmed cell death protein-1 blockade are rational approaches to prevent relapse. Here, we test CD19/22 dual-targeting CAR-T (AUTO3) plus pembrolizumab in relapsed/refractory LBCL (NCT03289455). End points include toxicity (primary) and response rates (secondary). Fifty-two patients received AUTO3 and 48/52 received pembrolizumab. Median age was 59 years (range, 27-83), 46/52 had stage III/ IV disease and median follow-up was 21.6 months. AUTO3 was safe; grade 1-2 and grade 3 cytokine release syndrome affected 18/52 (34.6%) and 1/52 (1.9%) patients, neurotoxicity arose in 4 patients (2/4, grade 3-4), and hemophagocytic lymphohistiocytosis affected 2 patients. Outpatient administration was tested in 20 patients, saving a median of 14 hospital days per patient. Overall response rates were 66% (48.9%, complete response [CR]; 17%, partial response). Median duration of remission (DOR) for CR patients was not reached and for all responding patients was 8.3 months (95% confidence interval [CI]: 3.0-not evaluable). 54.4% (CI: 32.8-71.7) of CR patients and 42.6% of all responding patients were projected to remain progression-free at ≥12 months. AUTO3 ± pembrolizumab for relapsed/refractory LBCL was safe and delivered durable remissions in 54.4% of complete responders, associated with robust CAR-T expansion. Neither dual-targeting CAR-T nor pembrolizumab prevented relapse in a significant proportion of patients, and future developments include next-generation-AUTO3, engineered for superior expansion in vivo, and selection of CAR binders active at low antigen densities.
引用
- Roddie C, Lekakis LJ, Marzolini MAV, et al. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma. Blood. 2023. PMID: 36821767. doi:10.1182/blood.2022018598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。